Early Detection of Glaucomatous Optic Neuropathy


About this study

The goal of this study is to determine if visual field assessment of the far periphery (60-4) and/or central visual field (10-2) enables earlier detection of  glaucomatous optic neuropathy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion criteria:

  • Patients with changes to the optic nerve head or OCT RNFL consistent with glaucomatous optic and normal SITA 24-2.
  • Adult patients 18 years of age or older
  • 20 normal subjects with healthy eyes.  Any ocular pathology that limits the subject’s visual acuity or visual field will not be invited to participate in the study.

Exclusion criteria:

  • Patients with ocular pathology that may adversely affect visual field testing including non-glaucomatous optic neuropathy or macular disease.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Cheryl Khanna, M.D.

Open for enrollment

Contact information:

Sepideh Jamali Dogahe M.D.

(507) 293-1807


More information


Publications are currently not available